Etoposide Teva Dosage/Direction for Use

Parenteral drug products should be inspected visually for particulate matter and discoloration, prior to administration, whenever solution and container permit. Etoposide should be given only by slow intravenous infusion (usually over a 30- to 60-minute period), since hypotension has been reported as a possible side effect of rapid intravenous injection. The dosage should be modified to take into account the myelosuppressive effects of other drugs in combined drug therapy, or the effects of prior x-ray therapy.
Refractory Testicular Tumors, Hodgkin's Disease, Malignant (non-Hodgkin's) Lymphomas Especially of the Histiocytic Variety, Acute Non-Lymphocytic Leukemia: The usual dose of Etoposide for Injection Concentrate in combination with other approved chemotherapeutic agents, ranges from 50-1 00 mg/m²/day on days 1 through 5 to 100 mg/m²/day on days 1, 3 and 5.
Small Cell Lung Cancer: The dose of Etoposide for Injection Concentrate, in combination with other approved chemotherapeutic drugs, ranges from 35 mg/m²/day for 4 days to 50 mg/m²/day for 5 days. Chemotherapy courses are repeated at 3- to 4-week intervals after adequate recovery from any toxicity.
Use in Pediatrics: Safety and efficacy for use in children have not been established.